Phase 3 Uveitis Trial, Not Yet Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with a specific type of eye inflammation (uveitis) that is not located at the front of the eye and is not caused by an infection.
- Your uveitis has not improved despite trying at least one biological medication (such as anti-TNF alpha or tocilizumab).
- You are able to stop your current biological and certain immunosuppressive medications for at least 10 days before joining the trial.
Who may not be able to join:
- Your uveitis is only in the front part of the eye (anterior uveitis).
- Your uveitis is caused by an infection.
- Your uveitis is so severe that it requires urgent treatment with corticosteroids given directly into a vein.
- Your vision in at least one eye is already severely reduced beyond a certain level (confirm with trial site).
- You have cloudiness in the cornea or lens that blocks a clear view of the back of the eye, or that may need cataract surgery during the study.
- You have a known allergy or sensitivity to the study drug, baricitinib, or any of its ingredients.
- You have a condition that prevents your pupils from being dilated for eye examination.
- You have severe glaucoma in either eye that has not responded to treatment.
- You only have one functioning eye.
- You have previously been treated with a type of medication called JAK inhibitors.
- You had a corticosteroid injection in or around the eye within the past 1 to 3 months (depending on the type of injection — confirm with trial site).
- You need to take certain other biological medications for inflammation affecting other parts of your body during the study period.
- You are currently taking certain medications that strongly interact with the study drug, such as probenecid, leflunomide, or teriflunomide.
- You received a live or live-attenuated vaccine (such as MMR or chickenpox vaccine) within 15 days before joining the trial.
- You have had cancer in the past 5 years, with the exception of certain non-spreading skin cancers.
- You have a personal history of blood clots in your veins (such as deep vein thrombosis or pulmonary embolism).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Mathilde LECLERCQ, MD, University Hospital, Rouen
Phone: +3323288
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of patients with complete remission
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.